A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

Conditions

Early-Onset Alzheimer Disease

Interventions / Drugs

ALN-APP Placebo

View on ClinicalTrials.gov ↗

Sponsor

ALNY

Alnylam Pharmaceuticals

RNAi Therapeutics

F28/100

Study Details

Enrollment60 participants

Primary Completion—

Lead SponsorAlnylam Pharmaceuticals

Data Retrieved2026-04-11 02:53:26.219358+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.